ProCE Banner Activity

Optimizing Heart Failure Care: A Guide to GDMT and SGLT2 Inhibitors 

PDF

This evidence-based, downloadable resource serves two key roles: educating patients on the benefits of guideline-directed medical therapy (GDMT), including SGLT2 inhibitors, regardless of symptoms, and providing healthcare providers with a structured conversation guide. Use it as a roadmap for patient counseling during office visits to optimize heart failure therapy.

Released: March 14, 2025

Expiration: March 13, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Disclosure

Primary Author

Javed Butler, MD, MPH, MBA

President of the Baylor Scott and White Research Institute
Senior Vice President for the Baylor Scott and White Health
Maxwell A. and Gayle H. Clampitt Endowed Chair
Dallas, Texas
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi

Javed Butler, MD, MPH, MBA: consultant/advisor/speaker: Abbott, Adaptyx, American Regent, Amgen, Applied Therapeutics, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Behring, CVRx, Cytokinetics, Edwards, Faraday, Imbria, Impulse Dynamics, Innolife, Inventiva, Lexicon, Lilly, Medtronics, Merck, Owkin, Novartis, Novo Nordisk, Pharmacosmos, PharmaIN, Prolaio, Regeneron, Renibus, Roche, Secretome, Vifor, Zoll.

Ty J. Gluckman, MD, MHA

Medical Director
Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

Ty J. Gluckman, MD, MHA, has no relevant financial relationships to disclose.